Mr. John Fowler reports

SUPREME CLOSES WARRANT INCENTIVE PROGRAM

Supreme Pharmaceuticals Inc. has closed the limited-time incentive program, which commenced on Feb. 16, 2016. Pursuant to the incentive program, Supreme received aggregate proceeds of $1,013,654.22 through the issuance of 3,167,646 common shares and 3,167,646 common share purchase warrants. For more details regarding the incentive warrants, please see the company's news release dated Feb. 16, 2016.

"We continue to receive strong support from our existing shareholder base. We have been busy as a company during the licensing process to ensure we hit the ground running," stated John Fowler, president of Supreme. "This incentive program further adds to our treasury and will allow us to quickly execute on our business plan, which is focused on continually improving two key metrics: the cost of production and our ability to scale. I must thank our shareholders and the local community for consistently supporting our vision. Finally, I want to applaud my team in Kincardine, who were able to obtain the Marihuana for Medical Purposes Regulations (MMPR) licence with zero deficiencies after only a single inspection."

In connection with the grant of a licence to cultivate medical marijuana issued to Supreme's wholly owned subsidiary, Advanced Medical Marihuana Canada (AMMCan), the company issued 1.47 million common shares of Supreme to officers, directors, consultants and other parties owed to fulfill success-based contractual obligations.

We seek Safe Harbor.